Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E.

Cancer Immunol Res. 2018 Jun;6(6):658-670. doi: 10.1158/2326-6066.CIR-17-0675. Epub 2018 Apr 5.

PMID:
29622580
2.

IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M.

Blood. 2012 Feb 9;119(6):1407-17. doi: 10.1182/blood-2011-06-363564. Epub 2011 Dec 19.

3.

MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.

Aricò E, Monque DM, D'Agostino G, Moschella F, Venditti M, Kalinke U, Allen DJ, Stewart JP, Nash AA, Belardelli F, Ferrantini M.

Vaccine. 2011 May 23;29(23):3935-44. doi: 10.1016/j.vaccine.2011.03.092. Epub 2011 Apr 8. Erratum in: Vaccine. 2012 Apr 26;30(20):3145. Stewart, James P [added].

PMID:
21481326
4.

Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.

Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M.

PLoS One. 2011 Feb 28;6(2):e17364. doi: 10.1371/journal.pone.0017364.

5.

IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.

Lattanzi L, Rozera C, Marescotti D, D'Agostino G, Santodonato L, Cellini S, Belardelli F, Gavioli R, Ferrantini M.

Immunobiology. 2011 May;216(5):537-47. doi: 10.1016/j.imbio.2010.10.003. Epub 2010 Oct 21.

PMID:
21093097
6.

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.

Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L.

Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12.

7.

IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

Santini SM, Lapenta C, Santodonato L, D'Agostino G, Belardelli F, Ferrantini M.

Handb Exp Pharmacol. 2009;(188):295-317. doi: 10.1007/978-3-540-71029-5_14. Review.

PMID:
19031032
8.

Biotherapy of cancer: break the barriers to foster translation of knowledge.

Ferrantini M, Lombardo C, Moretti F, Belardelli F.

Tumori. 2008 Mar-Apr;94(2):182-7.

PMID:
18564605
9.

The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.

Mignot G, Ullrich E, Bonmort M, Ménard C, Apetoh L, Taieb J, Bosisio D, Sozzani S, Ferrantini M, Schmitz J, Mack M, Ryffel B, Bulfone-Paus S, Zitvogel L, Chaput N.

J Immunol. 2008 May 15;180(10):6477-83.

10.

Dendritic cells and cytokines in immune rejection of cancer.

Ferrantini M, Capone I, Belardelli F.

Cytokine Growth Factor Rev. 2008 Feb;19(1):93-107. Epub 2007 Dec 3. Review.

PMID:
18054517
11.

Cytokines, dendritic cells and immunological rejection.

Ferrantini M, Belardelli F.

Cytokine Growth Factor Rev. 2008 Feb;19(1):1-2. Epub 2007 Dec 3. No abstract available.

PMID:
18054515
12.

Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

Ferrantini M, Capone I, Belardelli F.

Biochimie. 2007 Jun-Jul;89(6-7):884-93. Epub 2007 Apr 21. Review.

PMID:
17532550
13.

International meeting "Immunotherapy of cancer: challenges and needs".

Ferrantini M, Capone I, Marincola FM, Parmiani G, Belardelli F.

Cancer Immunol Immunother. 2007 Apr;56(4):581-5. Epub 2006 Nov 28.

PMID:
17131119
14.

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L.

Cancer Res. 2006 May 1;66(9):4943-51.

15.

International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?

Belardelli F, Ferrantini M, Parmiani G, Schlom J, Garaci E.

Cancer Res. 2004 Sep 15;64(18):6827-30.

16.
17.

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.

Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2137-46.

18.

Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.

Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M.

J Immunol. 2003 May 15;170(10):5195-202.

19.

Humoral immune response and protection from viral infection in mice vaccinated with inactivated MHV-68: effects of type I interferon.

Aricò E, Robertson K, Allen D, Ferrantini M, Belardelli F, Nash AA.

J Interferon Cytokine Res. 2002 Nov;22(11):1081-8.

PMID:
12513907
20.

Cytokines as natural adjuvants for vaccines: where are we now?

Rizza P, Ferrantini M, Capone I, Belardelli F.

Trends Immunol. 2002 Aug;23(8):381-3. No abstract available.

PMID:
12133794
21.

Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.

Indraccolo S, Gola E, Rosato A, Minuzzo S, Habeler W, Tisato V, Roni V, Esposito G, Morini M, Albini A, Noonan DM, Ferrantini M, Amadori A, Chieco-Bianchi L.

Gene Ther. 2002 Jul;9(13):867-78.

22.

Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.

Matarrese P, Di Biase L, Santodonato L, Straface E, Mecchia M, Ascione B, Parmiani G, Belardelli F, Ferrantini M, Malorni W.

Am J Pathol. 2002 Apr;160(4):1507-20.

23.
24.

Cytokines as a link between innate and adaptive antitumor immunity.

Belardelli F, Ferrantini M.

Trends Immunol. 2002 Apr;23(4):201-8. Review.

PMID:
11923115
25.

Interferon-alpha in tumor immunity and immunotherapy.

Belardelli F, Ferrantini M, Proietti E, Kirkwood JM.

Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34. Review.

PMID:
11900988
26.

Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.

Santodonato L, Ferrantini M, Palombo F, Aurisicchio L, Delmastro P, La Monica N, Di Marco S, Ciliberto G, Du MX, Taylor MW, Belardelli F.

Cancer Gene Ther. 2001 Jan;8(1):63-72.

27.

Conference on cancer vaccines.

Schadendorf D, Belardelli F, Ferrantini M, Parmiani G, Colombo MP.

Cancer Immunol Immunother. 2000 Jul;49(4-5):281-4. No abstract available.

PMID:
10941912
28.

Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications.

Ferrantini M, Belardelli F.

Semin Cancer Biol. 2000 Apr;10(2):145-57. Review.

PMID:
10936064
29.

Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach.

Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, Santi L, Noonan DM.

Am J Pathol. 2000 Apr;156(4):1381-93.

30.

Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha.

Mecchia M, Matarrese P, Malorni W, D'Agostino G, Sestili P, Santini SM, Gauzzi MC, Venditti M, Mazzocchi A, Parmiani G, Belardelli F, Ferrantini M.

Gene Ther. 2000 Jan;7(2):167-79.

31.

Type I consensus IFN (IFN-con1) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity in sCID mice.

D'Agostino G, Aricò E, Santodonato L, Venditti M, Sestili P, Masuelli L, Coletti A, Modesti A, Picchio G, Mosier DE, Ferrantini M, Belardelli F.

J Interferon Cytokine Res. 1999 Nov;19(11):1305-16.

PMID:
10574624
32.

Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.

Rozera C, Mecchia M, Gresser I, Bandu MT, Proietti E, Venditti M, Sestili P, Santini SM, Fais S, Belardelli F, Ferrantini M.

Cancer Gene Ther. 1999 May-Jun;6(3):246-53.

33.

Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.

Rozera C, Carlei D, Lollini PL, De Giovanni C, Musiani P, Di Carlo E, Belardelli F, Ferrantini M.

Am J Pathol. 1999 Apr;154(4):1211-22.

34.

The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.

Belardelli F, Ferrantini M, Santini SM, Baccarini S, Proietti E, Colombo MP, Sprent J, Tough DF.

Cancer Res. 1998 Dec 15;58(24):5795-802.

35.

Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells.

Rossi I, Nicoletti G, Landuzzi L, Frabetti F, De Giovanni C, Nanni P, Musiani P, Ferrantini M, Belardelli F, Lollini PL.

Clin Exp Metastasis. 1998 Feb;16(2):123-8.

PMID:
9514093
36.

Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines.

Santodonato L, D'Agostino G, Santini SM, Carlei D, Musiani P, Modesti A, Signorelli P, Belardelli F, Ferrantini M.

Gene Ther. 1997 Nov;4(11):1246-55.

37.

Extracellular matrix remodelling in a murine mammary adenocarcinoma transfected with the interferon-alpha 1 gene.

Scarpa S, Giuffrida A, Palumbo C, Vasaturo F, Signorelli P, Forni G, Modesti M, Ferrantini M, Belardelli F, Musiani P, Modesti A.

J Pathol. 1997 Jan;181(1):116-23.

PMID:
9072013
38.

Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-alpha 1 and herpes simplex thymidine kinase followed by ganciclovir.

Santodonato L, Ferrantini M, Gabriele L, Proietti E, Venditti M, Musiani P, Modesti A, Modica A, Lupton SD, Belardelli F.

Hum Gene Ther. 1996 Jan;7(1):1-10.

PMID:
8825863
39.

Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

Gabriele L, Kaido T, Woodrow D, Moss J, Ferrantini M, Proletti E, Santodonato L, Rozera C, Maury C, Belardelli F, et al.

Am J Pathol. 1995 Aug;147(2):445-60.

40.
41.

IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.

Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini PL, Nanni P, Forni G, et al.

J Immunol. 1994 Nov 15;153(10):4604-15.

PMID:
7963533
42.

Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.

Ferrantini M, Proietti E, Santodonato L, Gabriele L, Peretti M, Plavec I, Meyer F, Kaido T, Gresser I, Belardelli F.

Cancer Res. 1993 Mar 1;53(5):1107-12.

43.

Persistent infection of normal mice with human immunodeficiency virus.

Locardi C, Puddu P, Ferrantini M, Parlanti E, Sestili P, Varano F, Belardelli F.

J Virol. 1992 Mar;66(3):1649-54.

44.

Studies on the expression of H-2 antigens in non-metastatic and highly metastatic Friend erythroleukemia cells: correlation with the in vivo behaviour of tumor cells.

Ferrantini M, Pulciani S, Proietti E, Lespinats G, Anastasi A, Ciolli V, Rizza P, Belardelli F.

Clin Exp Metastasis. 1989 Nov-Dec;7(6):609-25.

PMID:
2476272
45.

Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver.

Elia G, Ferrantini M, Belardelli F, Proietti E, Gresser I, Amici C, Benedetto A.

Clin Exp Metastasis. 1988 Sep-Oct;6(5):347-62.

PMID:
3163957
47.

Membrane changes during tumor progression. Host control of metastatic spread.

Ferrantini M, Benedetto A, Elia G, Amici C, Belardelli F.

Ann Ist Super Sanita. 1988;24(1):159-70. Review. No abstract available.

PMID:
2454601
48.
50.

Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize.

Belardelli F, Ferrantini M, Maury C, Santurbano L, Gresser I.

Int J Cancer. 1984 Sep 15;34(3):389-95.

PMID:
6207117

Supplemental Content

Loading ...
Support Center